For treatment of patients with refractory NTRK fusion–positive cancers who are locally advanced, metastatic or where surgical resection is likely to result in severe morbidity and who have no satisfactory treatment options.
75% (independent review)
Final Score (after adjustments)
Preliminary non-curative score
Final non-curative Score
EMA (CHMP) July 2019
EMA conditional marketing authorisation September 2019